Steven L. Warner, Ph.D.
Affiliations: | 2005 | University of Arizona, Tucson, AZ |
Area:
PharmacologyGoogle:
"Steven Warner"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Laurence H. Hurley | grad student | 2005 | University of Arizona | |
| (Targeting the Aurora kinases to treat pancreatic cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Tyagi A, Jaggupilli A, Ly S, et al. (2023) TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax. Leukemia |
| Sakemura RL, Hefazi M, Cox MJ, et al. (2023) AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells. Cancer Immunology Research |
| Zhang Y, Arner EN, Rizvi A, et al. (2021) AXL inhibitor TP-0903 reduces metastasis and therapy resistance in pancreatic cancer. Molecular Cancer Therapeutics |
| Chan TY, Egbert CM, Maxson JE, et al. (2021) TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications. 12: 5337 |
| Taverna JA, Hung CN, DeArmond DT, et al. (2020) Single-cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer. Cancer Research |
| Garrido-Laguna I, Dillon PM, Anthony SP, et al. (2020) A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors. Journal of Clinical Oncology. 38: 3586-3586 |
| Jeon JY, Eisenmann E, Niu M, et al. (2020) Activity of the multikinase inhibitor TP‐0903 in RAS mutant acute myeloid leukemia The Faseb Journal. 34: 1-1 |
| Sinha S, Secreto CR, Boysen JC, et al. (2019) Β-Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance Blood. 134: 1739-1739 |
| Kumagai Y, Oishi J, Nakamura M, et al. (2019) Abstract 3969: TP-0903, a potent AXL receptor tyrosine kinase inhibitor, enhances the activity of anti-PD-1 therapy in a metastatic preclinical syngeneic model of breast cancer Cancer Research. 79: 3969-3969 |
| Mangelson R, Tyagi E, Peterson P, et al. (2019) Abstract 3804: The potent AXL kinase inhibitor, TP-0903, is active in pre-clinical models of EGFR positive non-small cell lung cancer Cancer Research |